Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics Inc (NASDAQ: INDP) is a preclinical-stage biotech company pioneering novel immunotherapies that activate both innate and adaptive immune responses. This dedicated news hub provides investors and researchers with essential updates on the company’s innovative bacterial platform and clinical progress.
Access real-time announcements about INDP’s Decoy20 candidate, strategic collaborations, and preclinical findings across multiple cancer types. Our curated collection includes press releases on trial designs, partnership developments, and scientific presentations – all critical for understanding the company’s position in immuno-oncology.
Key updates cover three focus areas: 1) Pipeline advancements in colorectal/pancreatic cancers and lymphoma 2) Mechanism of action insights from TLR/STING pathway activation 3) Strategic initiatives enhancing combination therapy potential. Bookmark this page for unfiltered access to primary source materials that inform investment and research decisions.
Indaptus Therapeutics (Nasdaq: INDP) has announced a clinical supply agreement with BeiGene to evaluate novel cancer treatment combinations. The planned trial, expected to start in 2025, will combine BeiGene's checkpoint inhibitor tislelizumab with Indaptus' Decoy20, a broadly targeted, short-duration systemic immune stimulator.
Decoy20, when combined with a PD-1 inhibitor and an oral non-steroidal anti-inflammatory agent, demonstrated 80-100% tumor eradication rates in preclinical studies. The trial aims to improve outcomes in human patients with various cancers, including liver, colon, and pancreatic.
BeiGene will provide access to its PD-1 inhibitor and technical expertise to accelerate the clinical trial. Indaptus will seek FDA approval to initiate the combination trial. A conference call is scheduled for October 22, 2024, at 4:30 PM ET to discuss the agreement and future plans.
Indaptus Therapeutics (Nasdaq: INDP) has announced progress in its Phase 1 trial of Decoy20, its lead drug candidate for cancer and viral infection treatment. The Safety Review Committee has approved unrestricted enrollment of patients at the lower Decoy20 dose for weekly administration. The safety profile aligns with expectations, with the most notable treatment-related adverse events being Grade 2 Infusion Related Reaction and Grade 2 Hypotension, both transient.
Dr. Roger Waltzman, Chief Medical Officer, emphasized the importance of gathering more safety and efficacy data to guide combination therapy initiation next year. CEO Jeffrey Meckler expressed confidence in Decoy20's potential impact on cancer immunotherapy, with results expected in the coming months.
Indaptus Therapeutics (Nasdaq: INDP) announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will participate in a Lumanity webinar on October 23, 2024. The webinar, titled 'Adapting to Immuno-Oncology's R&D Challenges: Refocusing on Innate Immunity as a 'Next Big Thing' in Cancer Immunotherapy,' will explore strategies for modulating innate immune pathways in cancer treatment.
Dr. Newman will share insights from Indaptus' Decoy20 platform, which uses killed, non-pathogenic Gram-negative bacteria to stimulate both innate and adaptive immune responses. The company's unique 'pulse-prime' approach aims to target hard-to-treat cancers that haven't responded to other therapies.
The webinar will feature a panel of biotech leaders discussing the potential of harnessing innate immunity in combination with checkpoint inhibitors to improve cancer control. Dr. Newman emphasized the importance of advancing drugs that modulate innate immune pathways alongside adaptive pathway activation in the evolution of cancer therapy.
Indaptus Therapeutics (Nasdaq: INDP) announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Jeffrey A. Meckler will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group. The event is scheduled for Wednesday, October 16, 2024, at 11:00 AM ET.
The summit, taking place virtually from October 15 to 17, 2024, offers an opportunity for investors to gain insights into Indaptus Therapeutics' developments. A webcast of the fireside chat will be available at https://m-vest.com/events/healthcare-10152024. Additionally, Mr. Meckler will be available for one-on-one meetings throughout the summit, providing further engagement opportunities for interested parties.
Indaptus Therapeutics (Nasdaq: INDP) reports encouraging safety data for its Decoy20 clinical program. The independent Safety Review Committee has approved the continuation of dosing at a lower Decoy20 dose weekly and the initiation of dosing at a higher Decoy20 dose weekly. The safety profile aligns with Decoy20's mechanism of action, with mild-to-moderate treatment-related adverse events resolving quickly.
Dr. Roger Waltzman, Chief Medical Officer, states the company aims to evaluate patients receiving two distinct weekly doses to identify potential monotherapy activity and gather safety data for future combination therapy. CEO Jeffrey Meckler notes that enrolling multiple patients at two different weekly doses should accelerate trial progress. The company plans to provide further updates later in the year.
Indaptus Therapeutics (Nasdaq: INDP) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. CEO Jeffrey A. Meckler will present a corporate overview on September 9, 2024, available on-demand starting at 7:00 AM Eastern Time.
The presentation will be accessible via webcast on the Indaptus website's investor relations section, with a replay available for approximately 90 days post-event. Meckler will also be available for one-on-one meetings throughout the conference. Interested parties can request meetings and register for the conference through the provided link.
Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed a $3 million registered direct offering and private placement, netting $2.5 million
- Advancing Decoy20 clinical trial to weekly dosing
- Presented data at ASCO and AACR meetings
- R&D expenses increased to $1.7 million in Q2 2024
- G&A expenses rose to $2.4 million in Q2 2024
- Loss per share was $0.47 for Q2 2024
- Cash and equivalents stood at $7.3 million as of June 30, 2024
- Current cash expected to support operations into Q1 2025
Indaptus Therapeutics (Nasdaq: INDP) has announced a $3.0 million registered direct offering and concurrent private placement. The company will issue and sell 1,643,837 shares of common stock at $1.825 per share, along with unregistered warrants to purchase an equal number of shares. The warrants, exercisable at $1.70 per share, will have a five-year term. Paulson Investment Company, is acting as the exclusive placement agent. The offering is expected to close around August 8, 2024. Indaptus plans to use the net proceeds to fund research and development activities and for working capital and general corporate purposes.
Indaptus Therapeutics (Nasdaq: INDP), a clinical stage biotech company, will present new data on its lead product candidate, Decoy20, at the STING & TLR-Targeted Therapies Summit in San Diego on June 19-20, 2024. Chief Scientific Officer Dr. Michael Newman, newly named chair of the Summit, will present at 9:15 a.m. on June 20th, discussing the validation of the company’s 'Pulse-Prime' hypothesis through initial clinical data on Decoy20. CEO Jeffrey Meckler highlighted the company's advancements in immuno-oncology and its novel approach using engineered killed bacteria to stimulate the immune system in patients with advanced solid tumors.
Indaptus Therapeutics (Nasdaq: INDP) announced that Dr. Roger Waltzman, Chief Medical Officer, will present new data on their lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024. The presentation will cover preliminary results from an ongoing Phase 1 study involving Decoy20, an intravenous treatment aimed at stimulating the immune system using killed bacteria, targeting patients with advanced solid tumors. CEO Jeffrey Meckler expressed optimism about the findings and the opportunity to share continued updates.
FAQ
What is the current stock price of Indaptus Therapeutics (INDP)?
What is the market cap of Indaptus Therapeutics (INDP)?
